The effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade on the course of acute respiratory distress syndrome in COVID-19 patients
- Funded by Novo Nordisk Foundation
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Known Financial Commitments (USD)
$533,600Funder
Novo Nordisk FoundationPrincipal Investigator
N/A
Research Location
DenmarkLead Research Institution
Gentofte HospitalResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Clinical trials for disease management
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Randomized Controlled Trial
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
Many of the most severely affected COVID-19 patients suffer from hypertension and/or diabetes. A majority of them take antihypertensive drugs that inhibit the renin-angiotensin system (RAS). Through a randomized clinical trial and using Danish registers and databases as well as patient records, this project will determine whether it will be beneficial to continue or stop treating COVID-19 patients in need of hospitalization with RAS inhibitors.